Abivax SA (ABVX) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Abivax SA (ABVX) over the past year, gaining 74.9% versus a gain of 2.9%. Krystal Biotech is the larger company by market cap ($9.69 billion vs $7.77 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | KRYS |
|---|---|---|
| Share price | $89.05 | $327.30 |
| Market cap | $7.77B | $9.69B |
| 1-day change | +2.34% | +0.84% |
| YTD return | -33.97% | +32.76% |
| 1-year return | +2.94% | +74.86% |
| 5-year return | — | +571.80% |
| P/E ratio (TTM) | — | 41.02 |
| Forward P/E | — | 35.33 |
| EPS (TTM) | $-6.08 | $7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $389.13M |
| Revenue growth (YoY) | — | +33.94% |
| Net income (latest FY) | — | $204.83M |
| Operating margin | — | 41.45% |
| Net margin | — | 52.64% |
| 52-week high | $148.83 | $382.54 |
| 52-week low | $69.81 | $179.19 |
| Distance from 52-week high | -40.17% | -14.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.17% | +19.80% |
| Average volume | 1.11M | 381.18K |
| Shares outstanding | 87.27M | 29.60M |
| Employees | 98 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRYS has outperformed ABVX by 71.9 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
ABVX vs KRYS FAQ
Which is bigger, Abivax SA or Krystal Biotech?
Krystal Biotech (KRYS) is larger, with a market capitalization of $9.69B compared with $7.77B for Abivax SA (ABVX).
Which stock has performed better over the past year, ABVX or KRYS?
KRYS returned +74.86% over the past 12 months, compared with +2.94% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Krystal Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Abivax SA and Biotechnology: Biological Products (No Diagnostic Substances) for Krystal Biotech.